Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA

Atreya R, Schmitt H, Fischer SM, Neurath M, Rekalde X, Nagore D, Ametzazurra A (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Journal of Crohns & Colitis Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: S391-S391

Conference Proceedings Title: JOURNAL OF CROHNS & COLITIS

DOI: 10.1093/ecco-jcc/jjy222.678

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur) Sven Moritz Fischer Department of Paediatrics and Adolescent Medicine Markus Neurath Lehrstuhl für Innere Medizin I

Involved external institutions

Progenika Biopharma ES Spain (ES)

How to cite

APA:

Atreya, R., Schmitt, H., Fischer, S.M., Neurath, M., Rekalde, X., Nagore, D., & Ametzazurra, A. (2019). Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA. In JOURNAL OF CROHNS & COLITIS (pp. S391-S391). OXFORD: OXFORD UNIV PRESS.

MLA:

Atreya, Raja, et al. "Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA." Proceedings of the JOURNAL OF CROHNS & COLITIS OXFORD: OXFORD UNIV PRESS, 2019. S391-S391.

BibTeX: Download